Caprelsa (vandetanib tablets − AstraZeneca) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has differentiated thyroid carcinoma
• Disease is refractory to radioactive iodine therapy

Approval duration

1 year